PAXLOVID™ (nirmatrelvir/ritonavir) Patient information | Pfizer Medical Information

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

This medicine has provisional approval in Australia to treat COVID-19 in adults who are at increased risk of progression to hospitalisation or death. This approval has been granted on the basis of short-term efficacy and safety data. Evidence of efficacy and safety from ongoing trials continues to be gathered and assessed.

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Paxlovid™ Quick Finder

Paxlovid Education for Patients
Translated CMI Resources

Consumer Medicine Information (CMI) in the following languages are available: Arabic, Greek, Italian, Simplified Chinese, Traditional Chinese, and Vietnamese.
Report an adverse event

You may report an adverse event via email at: [email protected]. For concerns about the quality of a Pfizer product please call 1800 675 229.
Resources

Download Consumer Medicine Information

Product Information

Did you find an answer to your question? Yes No

Didn’t find what you were looking for? Contact us.

Call 1 800 675 229^*

^*9AM-5PM (AEST) Monday to Friday

Connect with Pfizer Medical Information regarding your medical question.

Medical Enquiry

Submit a medical question for Pfizer prescription products.

Pfizer Safety

Contact Pfizer Safety to report a suspected side effect or adverse event for PAXLOVID™.